Transmyocardial revascularisation (TMR) mortality data go to FDA:
This article was originally published in Clinica
Executive Summary
PLC Systems has submitted data from two recent Heart Laser trials to the US FDA in support of its PMA application. In the most recent study, laser revascularisation cut six month mortality by 63% compared with medical therapy in 100 patients with untreatable coronary artery disease and grade III or IV angina. Six-month mortality was 6% in laser patients compared with 16% in the medically treated patients